Biopharmaceuticals – A Global Market Overview

0
shares
Be First to Share ->
Share on Twitter
Share on Google+
Share on LinkedIn
Pin to Pinterest
Share on StumbleUpon
+
What's This?

London (PRWEB) November 07, 2013

The pharmaceutical R&D pipeline and industry have been witnessing greater degree of dependence on biopharmaceuticals. Development of these products is being undertaken by a growing number of players in the pharmaceutical industry, which include the big pharma companies as also generic drug manufacturers, who are also engaged in developing biosimilars. In conjunction with the traditional small biopharmaceutical companies, the new bigger entrants have been focused on continually expanding the global biologics pipeline, implying that the number and proportion of new pharmaceuticals being commercialized would increasingly comprise biopharmaceuticals and not small molecule drugs. As the cost of developing biopharmaceuticals and bringing them to market is generally much higher, offering enhanced profit margins, it comes as no surprise that the global pharmaceutical industry would continue to rely on biopharmaceuticals for profits and innovation, in addition to its very survival.

Even though the worldwide economic recession has been slow in recovering, the global pharmaceutical and biopharmaceutical industries have marched ahead, showing profitability and growth. According to estimates, more than 10k therapeutics are currently in the research and development stage, which include chemical substance pharmaceuticals or drugs and biotechnology-derived pharmaceuticals or biopharmaceuticals undergoing over 40k clinical trials. This translates into a significant increase from as little as half-a-decade back, indicating a conspicuous shift in the pharmaceutical industry from developing small molecule drugs to biopharmaceuticals for obtaining novel, ground-breaking and profitable solutions.

The report reviews, analyses and projects the biopharmaceuticals market (2010-2020) for global and the regional markets including North America, Europe, Asia-Pacific, South America and Rest of World. The regional markets further analyzed for 14 independent countries across North America – The United States, Canada and Mexico; Europe – Germany, the United Kingdom, France, Italy, Spain and Russia; Asia-Pacific – Japan, China and India; South America – Argentina and Brazil.

Biopharmaceuticals product segments analyzed in this study comprises Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and others. Therapeutic areas analyzed include Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and others. Biopharmaceuticals market, estimated at US$ 199.7 billion globally in 2013, is further projected to reach US$ 497.9 billion by 2020, growing at 13.5% CAGR between 2010 and 2020. Among different product segments, monoclonal antibodies (moAb) constitutes the largest product segment in the global biopharmaceuticals market accounting for an estimated share of 25.6% in 2013, equating to US$ 51.1 billion. In terms of therapeutic area, neurology applications is the largest market for global biopharmaceuticals with an estimated 2013 share of 28.2% valued at US$ 56.3 billion, and further expected reach a projected US$ 144.5 billion by 2020.

The study includes 249 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of market numbers. The statistical tables represent the data for the global market by geographic region, product segment and therapeutic area. This study profiles 25 key global players and 70 major players across North America – 24; Europe – 17; Asia-Pacific – 27 and Rest of World – 2. The report also provides the listing of the companies engaged in research and development, manufacturing and supply of biopharmaceuticals. The global list of companies covers addresses, contact numbers and the website addresses of 492 companies.

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION

1.1 Evolution of the Industry

1.2 Product Outline

1.2.1 What are biopharmaceuticals?

1.2.1.1 Description of Biopharmaceuticals

1.2.1.2 Commercialization of Biopharmaceuticals

1.2.1.3 Regulation of Biopharmaceuticals

1.2.1.4 Principal Categories of Biopharmaceuticals and their Uses

1.2.1.5 Large Scale Production of Biopharmaceuticals

1.2.1.5.1 Transgenic

1.2.2 Categorization of Biopharmaceuticals

1.2.2.1 Monoclonal Antibodies

1.2.2.1.1 Production of Monoclonal Antibodies

1.2.2.1.2 Primary Applications of Monoclonal Antibodies

1.2.2.1.3 Anti-Inflammatory Monoclonal Antibodies

1.2.2.1.4 Anti-Cancer Monoclonal Antibodies

1.2.2.1.5 Other Monoclonal Antibodies

1.2.2.1.6 Therapeutic Applications of Monoclonal Antibodies

1.2.2.1.7 Therapeutic Monoclonal Antibodies Approved by the FDA

1.2.2.2 Erythropoietin (EPO)

1.2.2.2.1 Functions of EPO

1.2.2.2.2 Medical Uses of EPO

1.2.2.2.2.1 Available Forms of EPO

1.2.2.3 Biotech Vaccines

1.2.2.3.1 Categories of Vaccines

1.2.2.3.2 Recombinant Vector Vaccines

1.2.2.3.3 Production of Recombinant Vector Vaccines

1.2.2.3.4 Positives and Negatives of Recombinant Vector Vaccines

1.2.2.4 Recombinant Human (RH) Insulin

1.2.2.4.1 Production of RH Insulin

1.2.2.5 Granulocyte Colony-Stimulating Factor (G-CSF)

1.2.2.5.1 Biological Role of G-CSF

1.2.2.5.2 Therapeutic Applications of G-CSF

1.2.2.5.3 Some Highlights of G-CSF

1.2.2.6 Interferons (IFNs)

1.2.2.6.1 Types of Interferons

1.2.2.6.2 Functions of Interferons

1.2.2.6.3 Disease Therapy with Interferons

1.2.2.6.4 Interferons and Drug Formulations

1.2.2.7 Human Growth Hormones

1.2.2.7.1 The Functioning of Human Growth Hormone

1.2.2.7.2 Clinical Importance of HGH

1.2.2.7.3 Use of HGH as a Medication

1.2.2.8 Other Biopharmaceuticals

1.2.2.8.1 Blood Factors (Factor VIII and Factor IX)

1.2.2.8.1.1 Factor VIII

1.2.2.8.1.2 Factor IX

1.2.2.8.2 Thrombolytic Agents (Tissue Plasminogen Activator)

1.2.2.8.3 Interleukin-Based Products

1.2.2.8.3.1 Human Interleukins

1.2.2.8.4 Tumor Necrosis Factor

1.2.2.8.5 Therapeutic Enzymes

2. KEY FACTS AND FIGURES OF BIOPHARMA INDUSTRY AND LATEST APPROVALS

2.1 Some Key Facts about the Biopharmaceutical Industry

2.2 Biopharmaceuticals Approved by the USFDA in 2012 and 2013 (To Date)

3. KEY MARKET TRENDS

3.1 Enhancing Industry Health and Standing

3.2 Spending and Investment in Biopharmaceuticals Rising

3.3 Shifts in Outsourcing Trends

3.4 Continuing but Slowing Mega M&A Activity with More Emphasis on Strategy

3.5 New and Small Companies Feeling the Pinch

3.6 Can “BRICS” Build Up the Biopharmaceutical Industry?

3.7 What Ails the Biopharmaceutical Product Pipeline?

3.8 R&D in Biopharmaceuticals Surpassing Drug R&D

3.9 Biopharmaceutical Companies Going Global

3.10 Developing Countries Forging Ahead with Biopharmaceutical Manufacturing

3.11 Manufacturing Processes Attaining Global Standardization

3.12 In Conclusion

4. KEY GLOBAL PLAYERS

Abbott Laboratories, Inc.

Amgen, Inc.

Astrazeneca PLC

BASF SE

Bayer AG

Biocon Ltd.

Biogen Idec

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Daiichi Sankyo Company Limited

Eli Lilly and Company

Genentech, Inc.

Glaxosmithkline, PLC

Hospira, Inc.

Johnson & Johnson, Inc.

LG Life Sciences

Novartis AG

Novo Nordisk A/S

Pfizer, Inc.

Ranbaxy Laboratories Ltd.

Roche Holding AG

Sanofi

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Ltd.

UCB S.A

5. KEY BUSINESS TRENDS

Completion of Inspiration’s Hemophilia Products Sale

Novozymes Biopharma and EpiVax Ink Research Agreement

Glenmark Pharmaceuticals SA Discovers and Initiates IND Studies for GBR 830

Navidea Establishes Strategic Alliance with Maimonides Medical Center

Bayer and Regeneron Kickoffs VEGF Trap-Eye Phase III Trial to Treat DME

Novartis Kickoffs Biopharmaceutical Unit Construction

Roche Partners Chiasma on Octreolin Development and Commercialization

Partnership between Refine Technology and Gallus BioPharmaceuticals for Continuous Cell Culture Processing

Navidea Biopharmaceuticals Completes NAV4694’s Clinical Trial

GVK Biosciences Inks Collaboration with Onconova therapeutics on Novel Cancer Drugs

Completion of Abbott’s Research-based Pharmaceuticals Business Spin-off Forms AbbVie

Bio-Rad Launches 2-DE/WB workflow for Anti-HCP Antibodies Assessment

Novozymes biopharma Unveils New Brand for its rAlbumin Product Line

Expansion of Cytovance Biologics’ mammalian production capabilities in 2013

GlaxoSmithKline Partners with Biological E. for Combination Vaccine Development

Baxter Takes Over Inspiration’s OBI-1 Assets

BASF Acquires Pronova BioPharma

Sutro Biopharma and Sanofi Pasteur form Alliance on Vaccine Production

Development of Pertussis mAb therapies Started by Synthetic Biologics and Intrexon Corporation

Teva Pharmaceuticals Establishes Strategic Alliance with Galena Biopharma on NeuVax

FDA Approves MycoTOOL PCR Mycoplasma Detection Kit of Roche

Boehringer Inks Manufacturing Supply Agreement with Apexigen for Cancer mAbs

Merck Signs Agreement with GE Healthcare to Use [18F] Flutemetamol for the Development of

MK-8931, BACE Inhibitor for AD

Galena Biopharma Collaborates with Leica Biosystems for HER2 Companion Diagnostic Development

ProMetic Life Sciences in Collaboration with NantPharma Develop Second Plasma-derived Biopharmaceutical

Pamorelin LA of Debiopharm Unveiled by Dr. Reddy’s in India to Treat Prostate Cancer

Inspiration’s OBI-1 for Acquired Hemophilia A Receives FDA’s Fast Track Designation

New Licensed Biopharmaceuticals Produced by Fujifilm Diosynth Biotechnologies

PAREXEL Establishes a Strategic Alliance with National Taiwan University Hospital

SAFC Broadens the line of PharmaGrade Raw Materials for Biopharmaceutical Production

ActoGeniX and Merck Form Research Pact

Sandoz Biopharmaceuticals Inaugurates Cellular and Molecular Biology Laboratory in Menges

Boehringer Ingelheim Introduces Smart-to-Launch Fast Track Project Transfer Process

Launch of Biopharmaceutical Contract Manufacturing Offering by Olympus Biotech

SAFC Establishes Strategic Alliance with CrystalGenomics

Global Phase 3 Study for Recombinant Human Insulin of Biocon Achieves Positive Outcome

Fujifilm Diosynth Partners with Piramal Healthcare in ADCs Contract Manufacturing

DSM Collaborates with Paranta Biosciences

Wacker Biotech Partners with XL-protein for PASylated Therapeutic Proteins Production

Implementation of Boehringer Ingelheim’s Flexible Biopharmaceutical Disposable Set-up

KUBio, Modular Biopharmaceutical Factory Inaugurated by GE Healthcare

Synthetic Biologics Kickoffs the Development of mAbs to Treat Acinetobacter Infections

Gallus BioPharmaceuticals Establishes Strategic Alliance with Roslin Cells for Cell Therapeutics’ Supply

Constellation Pharmaceuticals Forms Strategic Alliance with The Leukemia & Lymphoma Society on BET Inhibitor Development

Evotec AG Inks Collaboration with Aspireo

Boehringer Ingelheim Inks Collaboration with Servier and XOMA

Biochrom AG Acquired by Merck KGaA

Gallus BioPharmaceuticals Partners with Natrix Separations Inc.

Collaboration between Theorem Clinical Research and Gallus BioPharmaceuticals

GE Healthcare Establishes Strategic Alliance with iBio for Using Plant-based Technologies in Biopharmaceuticals Production

Daiichi Sankyo Plans to Initiate Japanese Ministry’s Biopharmaceuticals Unit Construction

Inspiration Biopharmaceuticals Places its Two IB1001 Clinical Trials on Hold

ProMetic Life Sciences Inks Collaboration with NantPharma for Plasma-derived Biopharmaceutical Development

Unveiling Bristol-Myers Squibb’s Coverage with US$ 35 Trefis Price Estimate

Saint-Gobain Introduces C-Flex ULTRA Pump Tubing Excelling the Competition

Launch of Boehringer Ingelheim’s Typical Brand Boehringer Ingelheim BioXcellence

Merck KGaA Establishes Alliance with Dr Reddy’s to Develop Biosimilar mAbs

Strategic Alliance of DSM to Offer Contract Manufacturing Services

Bharat Biotech and University of Maryland to Collaborate on iNTS Vaccine Development

Collaboration between Daiichi Sankyo and Coherus BioSciences on Biosimilars

Grace and Formac Pharmaceuticals Completes Silica-Based Drug Delivery Technology’s Clinical Trial

Celltrion Steps into CMO Business for Novel Drugs Production in Korea

Research Organics Acquired by Sigma-Aldrich

Introduction of Lean-to-Clinic Program by Boehringer Ingelheim

GE Healthcare Acquires Xcellerex to Spread out its Competences in the Emerging Biopharmaceutical Industry

Daiichi Sankyo Signs Research Collaboration and License Agreement with NGM

GE Healthcare Plans to Acquire Xcellerex to Enhance Biopharma Potencies

Expansion of Boehringer Ingelheim’s Biopharmaceutical Process Science Capabilities

Morria Biopharmaceuticals and Scynexis form Alliance to Sustain MRX-4 Activities

Boehringer Ingelheim Establishes Strategic Alliance with Xencor to Develop, Produce and Commercialize Biosuperior mAbs

Sigma-Aldrich Acquires BioReliance to Advance Biopharmaceuticals Production

Sigma-Aldrich Plans BioReliance Acquisition to Offer Biopharmaceutical Testing and Services

Bristol-Myers Squibb Marks Merger Agreement with Inhibitex

Initiation of Hospira’s Biosimilar EPO Phase III Clinical Trial in US

Strategic Alliance between GE Healthcare and M+W Group

Lonza Unveils pDNA Production Platform to Produce Microbial Biopharmaceuticals

Repligen Acquires Novozymes Biopharma Sweden AB

Simcere Inks Collaboration with Bristol-Myers Squibb for Developing BMS-795311

Novozymes Biopharma Partners with R-Tech Ueno to Supply Albucult

Inspiration Biopharmaceuticals starts the Second OBI-1’s Accur8 Clinical Trial

ASLAN Pharmaceuticals and Bristol-Myers Squibb form BMS-777607 Development Pact

Fujifilm Diosynth Biotechnologies Partners with ContraFect Corporation to Develop and Manufacture CF-301

Bayer HealthCare Restructure Collaboration with Onyx Pharmaceuticals

Boehringer Ingelheim Receives Frost & Sullivan Award for Biopharmaceutical Contract Manufacturing

Biocon Heralds Project Initiation to Establish Biopharmaceutical Manufacturing and R&D Unit in Bio-XCell

CMC Biologics and Inspiration Biopharmaceuticals Collaborate on IB1001 Manufacture

Expansion of Boehringer Ingelheim’s Fill and Finish Competences for Biopharmaceuticals

Introduction of BD Recharge by BD Biosciences to Augment Biopharmaceutical Protein Production

Fujifilm Partners with Mitsubishi in Biopharmaceutical Contract Manufacturing

Expansion of Fujifilm Diosynth Biotechnologies’ Mammalian Cell Culture Capacity

Xcellerex Inks Collaboration with Gallus BioPharmaceuticals

Strategic License Agreement between Sanofi and Glenmark Pharmaceuticals on GBR500

Inauguration of EMD Millipore’s Biopharmaceutical Technical Center in Shanghai

Novozymes Biopharma Launches Albufuse Flex Technology Developed by Joining Forces with the University of Oslo

Amgen’s Biopharmaceutical Development and Manufacturing Unit Acquired by Boehringer Ingelheim

Unveiling of All-in-one Chromatography System of Bio-Rad

Forest Laboratories and Allergy Asthma Research Institute Fall in SAFE-BioPharma Association

Ipsen Establishes Strategic alliance with bioMérieux in Theranostics

Inspiration Biopharmaceuticals Demonstrates Non-inferiority of IB1001

6. GLOBAL MARKET OVERVIEW

6.1 Global Market by Product Segment

6.1.1 Biopharmaceutical Product Market Overview by Global Region

6.1.1.1 Monoclonal Antibodies (moAb)

6.1.1.2 Erythropoietin

6.1.1.3 Biotech Vaccines

6.1.1.4 Recombinant Human (RH) Insulin

6.1.1.5 Granulocyte Colony-Stimulating Factor (G-CSF)

6.1.1.6 Interferons

6.1.1.7 Human Growth Hormones (HGH)

6.1.1.8 Other Biopharmaceuticals

6.2 Global Market by Therapeutic Area

6.2.1 Biopharmaceutical Therapeutic Area Market Overview by Global Region

6.2.1.1 Neurology

6.2.1.2 Infectious Diseases

6.2.1.3 Diabetes

6.2.1.4 Oncology

6.2.1.5 Cardiovascular

6.2.1.6 Other Therapeutic Areas

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW

1. NORTH AMERICA

1.1 North American Biopharmaceutical Market by Geographic Region

1.2 North American Biopharmaceutical Market by Product Segment

1.2.1 Biopharmaceutical Product Market Overview by North American Region

1.2.1.1 Monoclonal Antibodies (moAb)

1.2.1.2 Erythropoietin

1.2.1.3 Biotech Vaccines

1.2.1.4 Recombinant Human (RH) Insulin

1.2.1.5 Granulocyte Colony-Stimulating Factor (G-CSF)

1.2.1.6 Interferons

1.2.1.7 Human Growth Hormones (HGH)

1.2.1.8 Other Biopharmaceuticals

1.3 North American Biopharmaceutical Market by Therapeutic Area

1.3.1 Biopharmaceutical Therapeutic Area Market Overview by North American Region

1.3.1.1 Neurology

1.3.1.2 Infectious Diseases

1.3.1.3 Diabetes

1.3.1.4 Oncology

1.3.1.5 Cardiovascular

1.3.1.6 Other Therapeutic Areas

1.4 Major Market Players

Abbott Laboratories, Inc.

Alder Biopharmaceuticals Inc.

Alexion Pharmaceuticals, Inc

Amgen, Inc.

Analytical Biological Services Inc

Array Biopharma Inc.

Atlanta Biologicals, Inc

Baxter Bioscience Inc

Biogen Idec

Bristol-Myers Squibb Company

Charles River Laboratories International, Inc.

Eli Lilly and Company

Fujifilm Diosynth Biotechnologies

Genentech, Inc.

Genzyme Corporation

Hospira, Inc.

Johnson & Johnson

Millennium Pharmaceuticals, Inc.

Novozymes Biopharma US, Inc.

Onyx Pharmaceuticals, Inc.

Pfizer Inc

Seattle Genetics, Inc

Soligenix, Inc.

Teva North America

1.5 North American Biopharmaceutical Market Overview by Country

1.5.1 THE UNITED STATES

1.5.1.1 Biopharmaceutical Market by Product Segment

1.5.1.2 Biopharmaceutical Market by Therapeutic Area

1.5.2 CANADA

1.5.2.1 Biopharmaceutical Market by Product Segment

1.5.2.2 Biopharmaceutical Market by Therapeutic Area

1.5.3 MEXICO

1.5.3.1 Biopharmaceutical Market by Product Segment

1.5.3.2 Biopharmaceutical Market by Therapeutic Area

2. EUROPE

2.1 European Biopharmaceutical Market by Geographic Region

2.2 European Biopharmaceutical Market by Product Segment

2.2.1 Biopharmaceutical Product Market Overview by European Region

2.2.1.1 Monoclonal Antibodies (moAb)

2.2.1.2 Erythropoietin

2.2.1.3 Biotech Vaccines

2.2.1.4 Recombinant Human (RH) Insulin

2.2.1.5 Granulocyte Colony-Stimulating Factor (G-CSF)

2.2.1.6 Interferons

2.2.1.7 Human Growth Hormones (HGH)

2.2.1.8 Other Biopharmaceuticals

2.3 European Biopharmaceutical Market by Therapeutic Area

2.3.1 Biopharmaceutical Therapeutic Area Market Overview by European Region

2.3.1.1 Neurology

2.3.1.2 Infectious Diseases

2.3.1.3 Diabetes

2.3.1.4 Oncology

2.3.1.5 Cardiovascular

2.3.1.6 Other Therapeutic Areas

2.4 Major Market Players

3P Biopharmaceuticals S.L. (Spain)

Applikon Biotechnology B.V. (The Netherlands)

Astrazeneca Plc (United Kingdom)

BASF SE (Germany)

Bayer AG (Germany)

Boehringer Ingelheim GmbH (Germany)

Cellgenix GmbH (Germany)

Evotec AG (Germany)

Glaxosmithkline, PLC (United Kingdom)

Merck Serono S.A. (Switzerland)

Novartis AG (Switzerland)

Novo Nordisk A/S (Denmark)

Novozymes A/S (Denmark)

Pronova Biopharma ASA (Norway)

Roche Holding AG (Switzerland)

Sanofi (France)

UCB S.A. (Belgium)

2.5 European Biopharmaceutical Market Overview by Country

2.5.1 GERMANY

2.5.1.1 Biopharmaceutical Market by Product Segment

2.5.1.2 Biopharmaceutical Market by Therapeutic Area

2.5.2 THE UNITED KINGDOM

2.5.2.1 Biopharmaceutical Market by Product Segment

2.5.2.2 Biopharmaceutical Market by Therapeutic Area

2.5.3 FRANCE

2.5.3.1 Biopharmaceutical Market by Product Segment

2.5.3.2 Biopharmaceutical Market by Therapeutic Area

2.5.4 ITALY

2.5.4.1 Biopharmaceutical Market by Product Segment

2.5.4.2 Biopharmaceutical Market by Therapeutic Area

2.5.5 SPAIN

2.5.5.1 Biopharmaceutical Market by Product Segment

2.5.5.2 Biopharmaceutical Market by Therapeutic Area

2.5.6 RUSSIA

2.5.6.1 Biopharmaceutical Market by Product Segment

2.5.6.2 Biopharmaceutical Market by Therapeutic Area

2.5.7 REST OF EUROPE

2.5.7.1 Biopharmaceutical Market by Product Segment

2.5.7.2 Biopharmaceutical Market by Therapeutic Area

3. ASIA-PACIFIC

3.1 Asia-Pacific Biopharmaceuticals Market by Geographic Region

3.2 Asia-Pacific Biopharmaceuticals Market by Product Segment

3.2.1 Biopharmaceutical Product Market Overview by Asia-Pacific Region

3.2.1.1 Monoclonal Antibodies (moAb)

3.2.1.2 Erythropoietin

3.2.1.3 Biotech Vaccines

3.2.1.4 Recombinant Human (RH) Insulin

3.2.1.5 Granulocyte Colony-Stimulating Factor (G-CSF)

3.2.1.6 Interferons

3.2.1.7 Human Growth Hormones (HGH)

3.2.1.8 Other Biopharmaceuticals

3.3 Asia-Pacific Biopharmaceuticals Market by Therapeutic Area

3.3.1 Biopharmaceutical Therapeutic Area Market Overview by Asia-Pacific Region

3.3.1.1 Neurology

3.3.1.2 Infectious Diseases

3.3.1.3 Diabetes

3.3.1.4 Oncology

3.3.1.5 Cardiovascular

3.3.1.6 Other Therapeutic Areas

3.4 Major Market Players

Aurobindo Pharma Ltd. (India)

Beijing Sl Pharmaceutical Co Ltd (China)

Beijing Tiantan Biological Products Co Ltd (China)

Biocon Ltd. (India)

Biological E Limited (India)

Bukwang Pharmaceutical Co Ltd (South Korea)

Cadila Healthcare Limited (Zydus Cadila) (India)

Celltrion, Inc. (South Korea)

Cipla Ltd (India)

Daiichi Sankyo Company Limited (Japan)

Dainippon Sumitomo Pharma Co Ltd (Japan)

Glenmark Pharmaceuticals Limited (India)

GVK Biosciences Pvt Ltd (India)

Hualan Biological Engineering Inc (China)

LG Life Sciences (South Korea)

Ranbaxy Laboratories Ltd. (India)

RPG Life Sciences Limited (India)

Reliance Life Sciences Pvt Ltd (India)

Samsung Biologics Co Ltd (South Korea)

Sanofi India Limited (India)

SciGen Ltd. (Singapore)

Shanghai Institute of Biological Products (China)

Shantha Biotechnics Ltd (India)

Sun Pharmaceutical Industries Ltd (India)

Suven Life Sciences Ltd (India)

Takeda Pharmaceutical Company Limited (Japan)

Torrent Pharmaceuticals Limited (India)

3.5 Asia-Pacific Biopharmaceuticals Market by Country

3.5.1 JAPAN

3.5.1.1 Biopharmaceuticals Market by Product Segment

3.5.1.2 Biopharmaceuticals Market by Therapeutic Area

3.5.2 CHINA

3.5.2.1 Biopharmaceuticals Market by Product Segment

3.5.2.2 Biopharmaceuticals Market by Therapeutic Area

3.5.3 INDIA

3.5.3.1 Biopharmaceuticals Market by Product Segment

3.5.3.2 Biopharmaceuticals Market by Therapeutic Area

3.5.4 REST OF ASIA-PACIFIC

3.5.4.1 Biopharmaceuticals Market by Product Segment

3.5.4.2 Biopharmaceuticals Market by Therapeutic Area

4. SOUTH AMERICA

4.1 South American Biopharmaceuticals Market by Geographic Region

4.2 South American Biopharmaceuticals Market by Product Segment

4.2.1 Biopharmaceutical Product Market Overview by South American Region

4.2.1.1 Monoclonal Antibodies (moAb)

4.2.1.2 Erythropoietin

4.2.1.3 Biotech Vaccines

4.2.1.4 Recombinant Human (RH) Insulin

4.2.1.5 Granulocyte Colony-Stimulating Factor (G-CSF)

4.2.1.6 Interferons

4.2.1.7 Human Growth Hormones (HGH)

4.2.1.8 Other Biopharmaceuticals

4.3 South American Biopharmaceuticals Market by Therapeutic Area

4.3.1 Biopharmaceutical Therapeutic Area Market Overview by South American Region

4.3.1.1 Neurology

4.3.1.2 Infectious Diseases

4.3.1.3 Diabetes

4.3.1.4 Oncology

4.3.1.5 Cardiovascular

4.3.1.6 Other Therapeutic Areas

4.4 South American Biopharmaceutical Market by Country

4.4.1 ARGENTINA

4.4.1.1 Biopharmaceutical Market by Product Segment

4.4.1.2 Biopharmaceutical Market by Therapeutic Area

4.4.2 BRAZIL

4.4.2.1 Biopharmaceutical Market by Product Segment

4.4.2.2 Biopharmaceutical Market by Therapeutic Area

4.4.3 REST OF SOUTH AMERICA

4.4.3.1 Biopharmaceutical Market by Product Segment

4.4.3.2 Biopharmaceutical Market by Therapeutic Area

5. REST OF WORLD

5.1 Rest of World Biopharmaceutical Market by Product Segment

5.2 Rest of World Biopharmaceutical Market by Therapeutic Area

5.3 Major Market Players

D-Pharm Ltd. (Israel)

Teva Pharmaceutical Industries Ltd. (Israel)

PART C: GUIDE TO THE INDUSTRY

1. NORTH AMERICA

1.1 Canada

1.2 United States

2. EUROPE

2.1 Austria

2.2 Belgium

2.3 Denmark

2.4 France

2.5 Germany

2.6 Ireland

2.7 Lithuania

2.8 Norway

2.9 Spain

2.10 Sweden

2.11 Switzerland

2.12 The Netherlands

2.13 United Kingdom

3. ASIA-PACIFIC

3.1 Australia

3.2 China

3.3 Hong Kong

3.4 India

3.5 Indonesia

3.6 Japan

3.7 Malaysia

3.8 Singapore

3.9 South Korea

3.10 Taiwan

4. REST OF WORLD

4.1 Brazil

4.2 Israel

PART D: ANNEXURE

1. RESEARCH METHODOLOGY

2. THE QUESTIONNAIRE

3. FEEDBAC

Charts & Graphs

PART A: GLOBAL MARKET PERSPECTIVE

Chart 1: Evolution of Biopharma Industry in Past Decade (2004-2013)

Chart 2: The FDA Approved Monoclonal Antibodies – Antibody, Brand, Company, Mechanism of Action and Indication

Chart 3: Forms of EPO – EPO Form, Drug Name and Manufacturer

Chart 4: Types of Human Interferons based on Type of Receptor Used in Signaling – Interferon Type I, Interferon Type II and Interferon Type III

Chart 5: The List of Interleukins (IL-1 to IL 36) – Interleukin Name, Source, Target Receptors, Target Cells and Function

Chart 6: Global Biopharmaceuticals Market Analysis (2010-2020) in US$ Million

Chart 7: Global Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million

Chart 8: Glance at 2010, 2015 and 2020 Global Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals

Chart 9: Global Monoclonal Antibodies (moAb) Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million

Chart 10: Glance at 2010, 2015 and 2020 Global Monoclonal Antibodies (moAb) Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 11: Global Erythropoietin Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million

Chart 12: Glance at 2010, 2015 and 2020 Global Erythropoietin Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 13: Global Biotech Vaccines Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million

Chart 14: Glance at 2010, 2015 and 2020 Global Biotech Vaccines Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 15: Global Recombinant Human (RH) Insulin Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million

Chart 16: Glance at 2010, 2015 and 2020 Global Recombinant Human (RH) Insulin Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 17: Global Granulocyte Colony-Stimulating Factor (G-CSF) Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million

Chart 18: Glance at 2010, 2015 and 2020 Global Granulocyte Colony-Stimulating Factor (G-CSF) Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 19: Global Interferons Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million

Chart 20: Glance at 2010, 2015 and 2020 Global Interferons Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 21: Global Human Growth Hormones (HGH) Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million

Chart 22: Glance at 2010, 2015 and 2020 Global Human Growth Hormones (HGH) Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 23: Global Other Biopharmaceuticals Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million

Chart 24: Glance at 2010, 2015 and 2020 Global Other Biopharmaceuticals Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 25: Global Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million

Chart 26: Glance at 2010, 2015 and 2020 Global Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas

Chart 27: Global Biopharmaceuticals in Neurology Therapy Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million

Chart 28: Glance at 2010, 2015 and 2020 Global Biopharmaceuticals in Neurology Market Therapy Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 29: Global Biopharmaceuticals in Infectious Diseases Therapy Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million

Chart 30: Glance at 2010, 2015 and 2020 Global Biopharmaceuticals in Infectious Diseases Therapy Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 31: Global Biopharmaceuticals in Diabetes Therapy Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million

Chart 32: Glance at 2010, 2015 and 2020 Global Biopharmaceuticals in Diabetes Therapy Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 33: Global Biopharmaceuticals in Oncology Therapy Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million

Chart 34: Glance at 2010, 2015 and 2020 Global Biopharmaceuticals in Oncology Therapy Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 35: Global Biopharmaceuticals in Cardiovascular Therapy Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million

Chart 36: Glance at 2010, 2015 and 2020 Global Biopharmaceuticals in Cardiovascular Therapy Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

Chart 37: Global Biopharmaceuticals in Other Therapeutic Areas Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million

Chart 38: Glance at 2010, 2015 and 2020 Global Biopharmaceuticals in Other Therapeutic Areas Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

PART B: REGIONAL MARKET PERSPECTIVE

Chart 39: The Projection of Prospective Regions in terms of Market Growth for Biopharmaceuticals by Geography – Asia-Pacific, South America, Europe and North America

Chart 40: Global Biopharmaceuticals Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia–Pacific, South America and Rest of World in US$ Million

Chart 41: Glance at 2010, 2015 and 2020 Global Biopharmaceuticals Market Share (%) by Geographic Region – North America, Europe, Asia–Pacific, South America and Rest of World

NORTH AMERICA

Chart 42: North American Biopharmaceuticals Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million

Chart 43: Glance at 2010, 2015 and 2020 North American Biopharmaceuticals Market Share (%) by Geographic Region – United States, Canada and Mexico

Chart 44: North American Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million

Chart 45: Glance at 2010, 2015 and 2020 North American Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals

Chart 46: North American Monoclonal Antibodies (moAb) Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million

Chart 47: Glance at 2010, 2015 and 2020 North American Monoclonal Antibodies (moAb) Market Share (%) by Geographic Region – United States, Canada and Mexico

Chart 48: North American Erythropoietin Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million

Chart 49: Glance at 2010, 2015 and 2020 North American Erythropoietin Market Share (%) by Geographic Region – United States, Canada and Mexico

Chart 50: North American Biotech Vaccines Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million

Chart 51: Glance at 2010, 2015 and 2020 North American Biotech Vaccines Market Share (%) by Geographic Region – United States, Canada and Mexico

Chart 52: North American Recombinant Human (RH) Insulin Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million

Chart 53: Glance at 2010, 2015 and 2020 North American Recombinant Human (RH) Insulin Market Share (%) by Geographic Region – United States, Canada and Mexico

Chart 54: North American Granulocyte Colony-Stimulating Factor (G-CSF) Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million

Chart 55: Glance at 2010, 2015 and 2020 North American Granulocyte Colony-Stimulating Factor (G-CSF) Market Share (%) by Geographic Region – United States, Canada and Mexico

Chart 56: North American Interferons Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million

Chart 57: Glance at 2010, 2015 and 2020 North American Interferons Market Share (%) by Geographic Region – United States, Canada and Mexico

Chart 58: North American Human Growth Hormones (HGH) Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million

Chart 59: Glance at 2010, 2015 and 2020 North American Human Growth Hormones (HGH) Market Share (%) by Geographic Region – United States, Canada and Mexico

Chart 60: North American Other Biopharmaceuticals Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million

Chart 61: Glance at 2010, 2015 and 2020 North American Other Biopharmaceuticals Market Share (%) by Geographic Region – United States, Canada and Mexico

Chart 62: North American Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million

Chart 63: Glance at 2010, 2015 and 2020 North American Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas

Chart 64: North American Biopharmaceuticals in Neurology Therapy Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million

Chart 65: Glance at 2010, 2015 and 2020 North American Biopharmaceuticals in Neurology Market Therapy Share (%) by Geographic Region – United States, Canada and Mexico

Chart 66: North American Biopharmaceuticals in Infectious Diseases Therapy Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million

Chart 67: Glance at 2010, 2015 and 2020 North American Biopharmaceuticals in Infectious Diseases Therapy Market Share (%) by Geographic Region – United States, Canada and Mexico

Chart 68: North American Biopharmaceuticals in Diabetes Therapy Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million

Chart 69: Glance at 2010, 2015 and 2020 North American Biopharmaceuticals in Diabetes Therapy Market Share (%) by Geographic Region – United States, Canada and Mexico

Chart 70: North American Biopharmaceuticals in Oncology Therapy Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million

Chart 71: Glance at 2010, 2015 and 2020 North American Biopharmaceuticals in Oncology Therapy Market Share (%) by Geographic Region – United States, Canada and Mexico

Chart 72: North American Biopharmaceuticals in Cardiovascular Therapy Market Analysis (2010-2020) by Geographic Region – United States

Read the full report:

Biopharmaceuticals – A Global Market Overview

http://www.reportbuyer.com/countries/north_america/usa/biopharmaceuticals_global_market_overview.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

For more information:

Sarah Smith

Research Advisor at Reportbuyer.com

Email: query@reportbuyer.com

Tel: +44 208 816 85 48

Website: http://www.reportbuyer.com







Leave a Comment

Your email address will not be published. Required fields are marked *